AHSG and chronic kidney disease: Fetuin-A levels rise in both MAFLD and obesity-related CKD, potentiating lipid-driven inflammation, fibrogenesis, and adiponectin suppression; thus, Fetuin-A-mediated AMPK inhibition may represent a common pathological node [134].